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Background: Infections with non-tuberculous mycobacteria (NTM) represent an increasing
problem. Their clinical relevance is still largely unknown as well as predictors for mortality
in affected patients. The objective was to describe prevalence and clinical relevance of
different NTM and to identify risk factors for mortality.
Methods: Retrospective cohort study of 124 patients with NTM detection between January
2001 and December 2011. Clinical characteristics like symptoms and radiological appearance
were assessed at presentation. The primary outcome was all cause mortality during the
follow-up period. Univariate and multivariate survival analyses using Cox proportional hazard
models were employed for statistical analysis.
Results: Over the study period, the frequency of NTM isolation varied from 4 to 12 patients per) 43 387 7043; fax: þ31 (0) 43 387 5051.
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138 E.P.A.T. Gommans et al.year. Twenty-nine out of 124 patients (23%) had a clinically relevant infection, according to the
criteria of the American Thoracic Society (ATS). Mycobacterium avium was isolated most
frequently, but Mycobacterium kansasii, Mycobacterium malmoense and Mycobacterium xeno-
pi had the highest clinical relevance. Symptoms were mostly diverse and non-specific. On radi-
ology, cavities were observed more frequently than a nodular-bronchiectatic variant or
consolidation. In 75% of all patients, follow up time was more than two years. Median survival
was 6.5 years (95%CIZ 2.7e10.3). Factors significantly influencing survival time were haemop-
tysis (HRZ 0.2, 95%CIZ 0.1e0.6) and a consolidation on imaging (HRZ 5.1, 95%CI 1.4e18.2).
Conclusions: The presentation of an infection with NTM can be diverse and depends mainly on
the causative NTM pathogen. The most important predictor for increased mortality is the
radiological appearance of a consolidation.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Non-tuberculous mycobacteria (NTM) are increasingly
recognized as causative pathogens in pulmonary infections.
There are many factors which possibly contribute to the
increase in frequency of NTM isolation, e.g., more sensitive
laboratory techniques, the decrease of cross-immunity
since the decreasing prevalence of tuberculosis, popula-
tion aging and a longer survival period of patients with
chronic diseases like chronic obstructive pulmonary disease
(COPD) [1e6]. Increased awareness of the disease might
also influence the frequency of detection [5].
Risk factors of susceptibility for this kind of infection are
largely unknown. The role of T-cells is proven to be
important in the defence against NTM [7]. Therefore,
human immunodeficiency virus (HIV)-infected patients are
quite vulnerable to an infection like this [7]. In the popu-
lation of patients without HIV, predisposing factors appear
to be other causes of immunosuppression or a locally
impaired immunity because of lung diseases like COPD and
bronchiectasis [7,8]. Disease caused by NTM can have a
broadly varying presentation and symptoms are often non-
specific. Not all isolated NTM cause an infection. Some
species are mainly found as a laboratory contaminant.
Some other species can colonise patients without causing
an infection, and are therefore also less clinically relevant.
For example among a population of patients with cystic
fibrosis, 13% was found to be carrier of an NTM, but not all
of them had symptoms caused by the NTM [9]. Besides the
difference in pathogenicity between NTM species and the
impact of an impaired immunity of the host, other pre-
dictors of poor outcomes are largely unknown. A better
understanding of these predictors can be helpful in de-
cisions about the treatment for an individual patient.
We therefore aimed to identify factors which can influ-
ence the presentation and outcome of patients with NTM.Methods
Study subjects
The databases of the microbiological laboratory at Maas-
tricht University Medical Center and Atrium Medical CenterHeerlen, the Netherlands, were used to identify patients
with detection of NTM during the period between January
2001 and December 2011. Inclusion criteria were 1.) a
positive culture result or polymerase chain reaction (PCR)
for NTM; and 2.) specimen origin from the respiratory tract.
Patients were excluded if they were younger than 18 years.
The combination of the databases from the two hospitals
provided 134 eligible patients, of which six patients were
excluded because they had infection with Mycobacterium
tuberculosis (tuberculosis) and no NTM, two were younger
than 18 years and two patients were excluded because
there was no clinical information available, except for the
culture results. Some of the included patients received
treatment in Orbis Medical Center. Their medical file was
available as well.
Study design
We performed a retrospective cohort study. Medical files of
all patients were reviewed using a pre-defined standardized
set of variables. Symptoms, possible risk factors for NTM
infection, and factors that may have influenced the pa-
tient’s outcome were recorded. Clinical information
assessed for each patient included symptoms, pre-existing
pulmonary diseases, non-pulmonary history, and medica-
tion, particularly immunosuppressants. Furthermore, we
registered infection parameters, renal and liver function
and arterial blood gasses, and lung function testing. The
guidelines of the ATS and Infectious Disease Society of
America (IDSA) [7] were applied to identify clinically rele-
vant cases. A patient was considered to have a clinically
relevant infection if diagnostic criteria from all of the
following three categories were met: 1.) clinical: pulmo-
nary symptoms and exclusion of other diagnoses; 2.)
radiological: nodular or cavitary opacities on chest radio-
graph, or a high-resolution CT scan that shows multifocal
bronchiectasis with multiple small nodules; 3.) microbio-
logical: positive culture results from at least two sputum
samples, one bronchial wash or lavage, or lung biopsy with
mycobacterial histopathological features and one positive
culture for NTM [7].
We listed the results of all cultures and PCR for atypical
mycobacteria assessed in sputum, bronchoalveolar lavage,
bronchial lavage, pleural effusion or lung biopsy material.
Table 1 Baseline characteristics of patients with pulmo-
nary NTM isolates.
N (%)
Total number of patients 124
Male gender 87 (70)
Age, years (mean, SD) 62 (14)
Body mass index (median, p25, p75) 22 (20e26)
Smoking (current or former) 93 (75)
Alcoholism 3 (2)
Miner 10 (8)
Pre-existing pulmonary diseasea 86 (69)
COPD 54 (44)
Asthma 14 (11)
Bronchiectasis 25 (20)
Cystic fibrosis 2 (2)
Lung cancerb 15 (12)
Tuberculosis in the past 7 (6)
Impaired immunitya
HIV 6 (5)
Leukopenia 5 (4)
Transplantation 2 (2)
Immunosuppressive medicationc 11 (9)
Diabetes 10 (8)
Otherwise impaired immunityd 1 (1)
Total n of patients with one or more
causes of impaired immunity
30 (24)
Risk factors for mortality in patients with NTM 139X-ray and chest CT scans obtained within 3 months of the
mycobacterial specimen collection were recorded. Reports
were read and all CT scans were reviewed by one or in case
of doubt two persons. All abnormal findings were reported
and the most important ones were divided into the
following categories: 1.) cavities, with or without other
findings; 2a.) nodules; 2b.) nodules and bronchiectasis; 3.)
consolidation without one of the above.
Antimycobacterial treatment was listed per patient with
name, type of antibiotic and length. For each patient the
given treatment was compared with the ATS guidelines and
with the drug sensitivity testings of the positive culture.
To check if and when a patient had died, the hospital
administration as well as the database of obituary notices
in the Netherlands [10] were consulted. In this database, an
obituary notice can be found from about 72% of all
deceased persons in the study region. Together with the
hospital administration and electronic patient files we were
able to determine survival status in 121 out of all 124 pa-
tients. With respect to all-cause mortality, patients who
were not found to be deceased and for whom entries in the
electronic patients files were found were classified to be
alive at the end of the study, in June 2012. 3 Patients with
incomplete data were censored at the date of hospital
admission. Mortality rate after two years was considered to
be a valuable end point, since in most cases treatment was
finished within this period.Unless otherwise stated, number of patients and the percent-
age of the total number of patients per group is presented.
a Patients can belong to more than one of these categories.
b Lung cancer: at the moment of inclusion as well as in the
past.
c Different combinations, including prednisolon more than
10 mg a day for at least 3 months, azathioprine, methotrexate,
anti TNF-a treatment, and different cytostatics.
d One patient with idiopathic CD4 lymphocytopenia. COPD:
chronic obstructive pulmonary disease. HIV: human immuno-
deficiency virus.Analysis
Data were reported as mean and standard deviation in case
of normally distributed data. If not normally distributed,
median and the 25th and 75th percentile were presented.
All percentages were calculated by dividing by the total
number of patients of which information about that specific
variable was available. c2 test, Fisher’s exact test and un-
paired t-tests were used to test for statistical significant
differences. For analysing all cause mortality, KaplaneMe-
ier curves were computed in combination with the Log-rank
test to compare mortality of different subgroups. Cox
regression analysis was used for the univariate and multi-
variate analysis of mortality in subgroups with correction
for important confounders including gender, age, and
smoking, and for all comorbidities. Hazard ratios in com-
bination with 95% confidence intervals were presented for
these analyses. A p-value <0.05 was considered to be sta-
tistically significant. SPSS statistics 19 was used for statis-
tical analysis.
The ethics committee of the Academic Hospital of
Maastricht approved the study.Results
A total of 124 patients were included of which 70% were
male (Table 1). The average age was 62 years (14) for men
and 60 years (14) for women. Seventy-five percent of all
patients were current or former smokers. Almost 70% of all
patients had pulmonary comorbidity, including COPD,
asthma, bronchiectasis, cystic fibrosis, history of tubercu-
losis, or lung malignancy. The prevalence of pulmonarycomorbidity was higher among men than in women (72
versus 62%).
In total, 24% of all patients in the study population had
one or more diseases or conditions which can cause an
impaired immune response (Table 1).
The origin of the respiratory specimen was sputum
(75%), bronchoalveolar lavage (3%), bronchial lavage (20%),
pleural effusion (2%) or lung biopsy material (0.5%). All
cases with a positive result in pleural effusion were positive
by culture only. Twenty-nine patients, (23%), had a clini-
cally relevant infection, according to ATS criteria [7]. In
patients who did not meet the criteria, most often the
typical radiological findings were lacking, or imaging was
not performed at all.Microbiology
Mycobacterium avium complex (MAC) was most frequently
isolated, (42 out of 124 patients (34%)), of which the ma-
jority had M. avium (28 patients). In the group of M. avium
about 35% had a clinically relevant infection, while none of
Figure 2 Radiology findings, shown for most common NTM
species. Percentages: number of patients with a certain finding
out of the group with a certain NTM species who had had a CT.
MAC: M. avium complex. RGM: rapid growing mycobacteria.
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ATS criteria. After MAC, the second most common was
Mycobacterium kansasii (15%, n Z 19). The clinical rele-
vance of M. kansasii was 52.6%. Mycobacterium gordonae
was the third frequent mycobacterium, found in 13%
(nZ 16), but was in none of the cases considered clinically
relevant. Furthermore Mycobacterium malmoense was
isolated in 6 patients, Mycobacterium xenopi in 3 patients,
and the three rapid growing mycobacteria Mycobacterium
abcessus, Mycobacterium chelonae and Mycobacterium
fortuitum, were detected in samples of 5, 4 and 5 patients,
respectively. Other mycobacteria were isolated only inci-
dentally. The frequency of isolation per species is pre-
sented in Fig. 1, as well as the percentage of patients with a
clinically relevant infection. Patients with M. malmoense,
xenopi or kansasii most frequently had a clinically relevant
infection, (more than 50%).
Symptoms
The most frequently reported symptoms were cough (66%),
mostly productive, dyspnoea (46%) and haemoptysis (27%).
Thoracic pain was reported in 19% of all cases, the same
percentage as for loss of weight. 16% reported fatigue or
malaise, also 16% had recurring fever or night sweat.
Radiology
Computer tomography (CT) was available from 83 patients
(67%). Cavities were described in 33 out of 83 patients
(40%), nodules or a combination of nodules with bronchi-
ectasis in 12 patients (14%), and consolidation without any
of the others (cavities, nodules or bronchiectasis) in 16
patients (19%). 27% of patients from whom a CT was avail-
able did not fit in one of these categories. Some of them
had no abnormalities, or only other findings that could not
be directly related to NTM. These findings were amongst
others: pleural pathology, pleural effusion, bullae, tumours
and atelectasis. In men, NTM related radiologic abnormal-
ities were found in 79% of all CTs, in women 62% had one of
the four findings mentioned before. When the abnormal-
ities per type of mycobacterium were compared (Fig. 2),
one can see that cavities were found most often in patients
with M. malmoense (83% of patients with this NTM) and M.
kansasii (60%). Nodules were most frequently seen in M.
kansasii as well (27%). Consolidations were mostly found
among patients with an M. avium complex (31% of allFigure 1 Number of patients per species. In black: number of pa
criteria. MAC: M. avium complex. In all respective patients only onpatients with M. avium). However, all these differences
were not statistically significant.
The location of the radiologic findings was in 34% of all
cases in the right upper lobe. For cavities, 50% were
localized in the right upper lobe. The remaining part of all
cavities was mostly found in the left upper lobe (28%).
Nodules were besides the right upper lobe often observed
diffusely spread (22%), and bronchiectasis had a second and
third favourite localization in the right lower lobe (21%) and
left upper lobe (18%). Consolidation was besides the right
upper lobe localized in all other lobes (13e18%), except for
the lingula.
Treatment
Antibiotic therapy was started in 51 patients (41.1%). In the
group having a clinically relevant infection 79% received
therapy, among the ones not meeting the ATS criteria 29%
were treated with antibiotics.
Survival
The mean follow-up period was 61 months (SD 41 months),
with a range from 3 to 158 months. Ninety patients were
followed for more than 2 years. A total of 58 patients died
during the study follow up. The median survival time in the
population was 78 months, corresponding to an average of
6.5 years (95% CI 32e123 months). The mortality rate was
9.2 per 100 patient-years.tients with a clinically relevant infection according to the ATS
e mycobacterium species was detected.
Table 2 Median survival and mortality rate per 100 pa-
tient years, presented per species of NTM.
Median survival
(months) (95% CI)
Mortality rate
(per 100
patient years)
Total 78 (32e123) 9.2
MAC 41 (0e95) 9.6
M. kansasii 39 (11e67) 9.6
M. malmoense 10 (0e38) 19.7
M. xenopi 7 (4e10) 15.9
Rapid growing
mycobacteria
78 (0e158) 10.0
M. gordonae a 6.4
a Median survival could be computed for M. gordonae, since
the survival curve did not fall to 0.5. MAC: Mycobacterium
avium complex. RGM: rapid growing mycobacteria.
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months 25% of all patients died. (Fig. 3) After about two
years a decline occurred in the number of deaths per year.
Patients with M. malmoense and M. xenopi had the lowest
median survival with ten and seven months, for patients
with M. kansasii the median survival was 39 months, in MAC
41 and for the rapid growing mycobacteria 78 months
(Table 2).
Regression analysis was used to examine the hazard ratio
per NTM species. M. avium complex was used as the
reference category since this is the most prevalent myco-
bacterium species. None of the other NTM categories had a
significantly higher or lower survival in comparison to M.
avium. After correction for the factors gender, age, smok-
ing, COPD, asthma, bronchiectasis, lung malignancy, HIV
and the use of immunosuppressive medication, the differ-
ences in survival between the species were even smaller
(Table 3).
In multivariate analysis, gender, age and smoking status
appeared not to have a significant effect on mortality. Pa-
tients with a lung malignancy had a hazard ratio of 2.9
(1.1e8.1) in comparison with patients without. COPD Gold
IV was the only stage of COPD compared with no COPD
which caused a significantly raised hazard ratio of 3.8
(1.4e10.5), as shown in Table 3. Hazard ratios for patients
with COPD Gold I, II and III were not significantly different
from patients without COPD, namely for COPD Gold I
(versus no COPD) HR 0.8 (95% CI 0.1e6.6), Gold II HR 0.8
(95% CI 0.2e3.0), Gold III HR 1.1 (95% CI 0.4e2.7).
While correcting for the same factors as stated before,
symptoms and radiologic findings were examined. The only
symptom that influenced mortality significantly was hae-
moptysis (see Table 4). A hazard ratio of 0.2 (0.1e0.6) was
found, which implies a better survival for patients with
haemoptysis. Patients with a consolidation on radiologic
investigation at the moment of diagnosis, had a significantly
higher mortality risk than patient who do not have a
consolidation. The hazard ratio was 5.1 (1.4e18.2). To have
a cavity, nodules or bronchiectasis, did not affect the
mortality risk. Also not of significant influence was theFigure 3 Survival. A: overall mortality. B: Survival per NTM specietreatment strategy, whether this was according to the ATS
guidelines or not, and whether it was concordant to sensi-
tivity testing or not. For antibiotic treatment in general,
the hazard ratio was 0.40 (0.1e1.2) for patients who
received treatment in comparison to patients who did not.
No significant difference was observed between the two-
year mortality rates of the four groups as shown in Fig. 4
(p Z 1.00).
Discussion
Our retrospective study of a cohort of 124 patients with an
NTM infection showed several interesting findings: The
frequency of NTM isolation has increased over the period
2001e2011 in these two Dutch centers. The clinical rele-
vance of NTM species varies broadly, as also symptoms and
radiological findings differ between species. Overall, cav-
ities were observed most frequently, consolidations are
predicting an increased mortality risk. The mortality among
patients with atypical mycobacteria differs per species,s. MAC: M. avium complex. RGM: rapid growing mycobacteria.
Table 3 Hazard ratio in univariate analysis and after correction for the factors gender, age, smoking, COPD, asthma, bron-
chiectasis, lung cancer, HIV and the use of immunosuppressive medication. NTM species divided in 5 categories, incidentally
isolated species are not included in this analysis. N Z 113.
NTM species Hazard ratio in
univariate analysis
95% CI Hazard ratio in
multivariate analysis
95% CI
M. avium complex (n Z 37) (reference category)
M. kansasii (n Z 19) 1.1 0.5e2.5 1.3 0.5e3.0
M. malmoense and xenopi (n Z 9) 1.9 0.8e4.6 1.2 0.4e3.5
RGM (n Z 10) 0.9 0.3e2.6 1.1 0.3e3.4
M. gordonae (n Z 15) 0.6 0.2e1.7 0.9 0.3e2.7
Male vs female 1.9 0.8e4.3 1.6 0.6e4.4
Age 1.0 1.0e1.0a 1.0 1.0be1.0
Smoking vs non-smoking 1.4 0.9e2.2 1.0 0.3e2.6
Gold IV vs no COPDd 2.4 0.9e6.7 3.8 1.4e10.5
Asthma 0.2 0.0e1.6 0.5 0.1e2.4
Bronchiectasis 0.8 0.3e1.9 1.1 0.5e2.5
Lung malignancy 4.0 1.9e8.7 2.9 1.1e8.1
HIV 1.1 0.3e3.5 5.0 1.0ce26.2
Immunosuppressive drug therapy 1.1 0.6e2.1 2.7 0.9e8.6
Bold indicates p<0.05.
a 95% CI for hazard ratio of age: 0.96e1.04.
b 95% CI for hazard ratio of age: 0.99e1.05.
c 95% CI for hazard ratio of HIV: 0.97e26.90.
d Hazard ratios for patients with COPD Gold I, II and III were not significantly different from patients without COPD, namely for COPD
Gold I (versus no COPD) HR 0.8 (95% CI 0.1e6.6), Gold II HR 0.8 (95% CI 0.2e3.0), Gold III HR 1.1 (95% CI 0.4e2.7). COPD: chronic
obstructive pulmonary disease. HIV: human immunodeficiency virus.
142 E.P.A.T. Gommans et al.and is also influenced by comorbidity like lung cancer and
severe COPD.
Twenty-nine patients (23.4%) had a pulmonary NTM
infection when applying the criteria of the ATS. The main
reason not meeting all ATS criteria was the lack of radio-
logic investigation. In this study, CT scans and X-rays were
only included if these were performed within 3 months of
the date of diagnosis, although this time limitation is not
demanded by the ATS. Since radiologic abnormalities can
develop after a few months, the time frame we used might
have been too narrow. We expect the percentage of pa-
tients with a clinically relevant infection to be under-
estimated for this reason. The clinical relevance of NTM
varies a lot in other populations. In a study conducted in
another part of The Netherlands, the Nijmegen-Arnhem
region (van Ingen et al., 2009), 25.0% out of 212 patients
met the ATS criteria [2], while in a Taiwanese study 48.8%
of 640 patients had a pulmonary infection [11]. They bothTable 4 Hazard ratio of symptoms. Correction for gender,
age, smoking, COPD, asthma, bronchiectasis, lung cancer,
HIV, and use of immunosuppressive medication.
Factor Hazard ratio in
multivariate analysis
95% CI
Cough 1.0 0.5e2.6
Dyspnoea 2.0 0.9e4.9
Haemoptysis 0.2 0.1e0.6
Thoracic pain 1.9 0.6e6.1
Fatigue/malaise 1.2 0.4e3.0
Weight loss 2.7 0.9e8.0
Fever/night sweat 0.4 0.1e1.5used the same 2007 ATS criteria as we did. A study con-
ducted in the United Kingdom in which the ATS criteria from
1997 were used, found an even higher percentage of clini-
cally relevant infections, namely 72% of 117 patients [12].
In this version of the ATS guideline from 1997 the radio-
logical criteria for NTM diagnosis were less strict in com-
parison to the version of 2007, but with regard to
microbiology, the number of required cultures was higher,
namely three instead of two sputum cultures [13].
In comparison with the study performed by van Ingen
et al. [2], with 212 patients with pulmonary NTM, some
differences in frequency of certain NTM species were
found. The percentage of M. kansasii in our population is
almost twice as high (15.3% versus 8.0%) [2]. One possible
explanation for this difference could be the fact that in the
region our study was conducted in, mining industry has
been very active in the past. But, in a subgroup of miners
we only found one patient with M. kansasii (10.0%). Ac-
cording to Cerda de Pelau et al. [14], this doesn’t exclude
an influence of coal mining. They studied the prevalence of
M. kansasii in a coal mining region and suggest that not
mine working per se is the main risk factor, but living in a
mining region in general [14]. Another species that was
more frequently isolated, was M. malmoense (4.8% in our
study, 1.4% in the Nijmegen-Arnhem region) [2]. The three
main rapid growing mycobacteria (RGM) were isolated
evidently less frequent than in Asian populations. Although
NTM in general are found at a higher prevalence among
Asian people compared to European (15 versus 8.3 per
100.000), the percentage caused by RGM is also higher [15].
45% of all isolated NTM were rapid growing mycobacteria in
a Taiwanese study, evidently higher than the 11% in our
population [11]. Clinical relevance of the different species
Figure 4 Two-year mortality for patients with and without a clinically relevant infection, who did and did not receive antibiotic
therapy. Percentage: number of patients who died within 2 years, out of all patients followed for at least 2 years. ‘Loss to follow
up’: patients followed for less than 2 years. ATSþ: patients with a real pulmonary infection caused by atypical mycobacteria,
according to the criteria of the American Thoracic Society.[7].
Risk factors for mortality in patients with NTM 143in our study is comparable with the findings of the Dutch
cohort study mentioned before. Less than 10% difference
was observed for M. avium, M. malmoense, M. xenopi and
M. gordonae. For M. kansasii, we recorded a clinical rele-
vance of 53%, while van Ingen et al. observed 71% clinically
relevant infections with M. kansasii [2]. The fact that
clinical relevance of M. kansasii is higher than most other
NTM corresponds to the findings of a recent Israeli study
[16].
On radiologic investigation, cavities were found most
often. When comparing the number of patients with fibro-
cavitary and nodular-bronchiectatic presentation, a ratio of
more than 3:1 was observed. This in contrast to findings of
Satyanarayana et al., [17] who found a ratio of 1:3. In
another Dutch study a ratio of 4:1 is reported. Cavities were
observed more often in men than in women. A predomi-
nance of female patients within the group with nodular or
bronchiectatic abnormalities could not be observed, in
contrast to what Shu et al. (2011) reported [3]. Abnormal-
ities on radiology were most frequently found in the right
upper lobe, which corresponds to the general predisposi-
tion of the right upper lobe for infection by inhaled path-
ogens. The majority of cavities were also localized in the
right upper lobe, similar to other studies [7,16]. Nodules
and bronchiectasis were not observed more frequently in
the middle lobe and lingula than in other lobes. This in
contrast to findings reported by Griffith et al. (2007) in the
ATS statement of 2007 [7]. A possible reason for this
discrepancy could be the small number of patients with
nodules and bronchiectasis in our study, which makes it
hard to describe a pattern with regard to localization. But it
is also possible that a real difference exists between our
study population and populations investigated in non-
European studies, as we also observed a different ratio of
patients with fibrocavitary disease and patients with
nodular-bronchiectatic disease. Differences in study design
and populations investigated might also be a reason why we
did not find an association between age and mortality as it
was found in the recent study of Hayashi et al. [18] They
performed a retrospective analysis of medical records of
634 HIV-negative patients specifically with MAC lung disease
treated at their institution in Saitama and found by multi-
variate Cox proportional hazard modelling that male sex,
older age, presence of systemic and/or respiratory comor-
bidity, non-nodular/bronchiectatic radiographic features,
body mass index (BMI) less than 18.5 kg/m2, anemia,hypoalbuminemia, and erythrocyte sedimentation rate
greater than or equal to 50 mm/h were negative prognostic
factors for all-cause mortality. If we compare our findings
with these findings it is obvious that our study included less
MAC patients. Most probably this is the main reason for the
lacking statistical association of age and mortality in our
study.
In line with Hayashi we found that pre-existent lung
disease like lung malignancy and severe COPD had an
important influence on mortality among patients with
NTM infections. Since these diseases have an important
influence on life expectancy in general, it’s hard to
determine their exact effect on the course of an NTM-
infection. Symptoms predicting a higher mortality risk
could not be identified. Patients with haemoptysis were
found to have a better survival than others. This seems to
be a counter-intuitive finding. However, it seems possible
that this symptom might represent an early warning sign
triggering faster and more intensive diagnostic approach.
This might result in a more intense work up and follow up
of patients with haemoptysis. Nevertheless the design of
our study does not allow drawing conclusions and more,
possibly prospective research is needed. Consolidation on
X-ray or CT turned out to be predictive for increased
mortality. Shu et al. (2011), who describe the course of
NTM infections stratified by radiologic pattern, also found
a higher mortality among patients with a consolidation.
After six months 25% of all patients with consolidations
had died, in contrast to 8% in the group with cavities and
3% among patients with the nodular-bronchiectatic
variant. They describe a few factors which possibly have
contributed to the high mortality among the patients with
a consolidation in their population. First, these patients
were found to have more comorbidities and a poorer
nutritional status. Second, the systemic inflammatory
process was more severe in comparison with the other
presentations of NTM disease. One additional factor could
be that only few patients with a consolidation received
anti-mycobacterial therapy, since the presentation is not
the most typical one [3]. In our population this is unlikely
to have played a role, since the percentage of patients
with a consolidation who received antimycobacterial
therapy was even higher compared to the total group (54%
versus 41%).
In a study of O’Connell et al. (2012), 16 patients with
NTM infections were post mortem investigated by autopsy.
144 E.P.A.T. Gommans et al.Consolidation and miliary nodules were mainly found in
patients with disseminated disease with pulmonary
involvement. In patients with a primary pulmonary infec-
tion, bronchiectasis, cavity formation and necrotizing
bronchocentric granulomatous inflammation predominated
[19]. The fact that consolidations were found mainly in
patients with disseminated disease can definitely be of in-
fluence on the mortality risk. But in our study population
this cannot be an explanation for the higher mortality risk
among patients with a consolidation, since only one patient
had disseminated disease.
Our study design does not allow commenting on the
underlying mechanisms but we can conclude that in this
study the presentation with a consolidation on radiology
was an evident risk factor for mortality among patients
with NTM. Hollings et al. (2002), who systematically
investigated CT scans of patients with pulmonary NTM
infections, also present frequencies of radiological find-
ings in pulmonary NTM infections. In their population of 55
patients, 58% had a consolidation on CT, compared to 36%
cavities and 22% reticular patterns [20]. In the present ATS
guideline, consolidations are not included in the radio-
logical criteria for pulmonary NTM infection. Because of
the number of patients with a consolidation and the
mortality risk among this group of patients, we think that
the radiological criteria for pulmonary NTM disease should
also include consolidations.
There are a few limitations in this study. We already
mentioned the shortcoming in radiological investigations
and therefore an underestimation of patients who have an
infection according to the ATS criteria. With regard to the
symptoms, a possible limitation is that we were only able
to document reported symptoms. In some cases, patients
were probably not interviewed systematically about all
symptoms associated with NTM infection, which might
have led to underestimation of the frequency of these
symptoms. In the same way, some other relevant infor-
mation like medical history, might have been missing in
some patient files. Furthermore, mortality could be
underestimated, because of the incompleteness of the
mortality databases we used in this study. Age was
not found to be related to mortality in our study. This
may be due to sample size and prevalence of significant
co-morbidity such as malignancies and chronic lung
disease.Conclusions
This study shows that the clinical relevance of NTM species
varies broadly, as both symptoms and radiological findings
differ between species. For NTM in general, the most
important predictor for mortality was the radiological
appearance; consolidation on CT at presentation of NTM
infection was associated with a higher mortality. Comor-
bidities like lung cancer and severe COPD were risk factors
as well. Differences in mortality between certain treatment
strategies could not be proven, because of the small sub-
categories. Prospective studies would be of great value for
this study objective, but will be hard to conduct because of
the low incidence of this disease. Pooling data with other
studies might also open up new perspectives.Conflicts of interest
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